文献速递妇产影像泌尿生殖MR

2023年FIGO分期修订对FIGO 2009 I期子宫内膜癌MRI诊断准确性的影响

Impact of the 2023 FIGO staging revision on MRI diagnostic accuracy in FIGO 2009 stage I endometrial cancer.
PubMed 文献 · Abdom Radiol (NY) · 2025-08-26

本研究回顾性纳入432例经病理确诊的FIGO 2009 I期子宫内膜癌患者,比较2009与2023版FIGO分期下术前MRI分期的诊断效能。非侵袭性肿瘤中2009版分期准确性优于2023版(kappa 0.82 vs 0.66,p=0.0029),侵袭性肿瘤中两版无显著差异(p=0.160)。MRI对深肌层浸润诊断敏感度87.0%、特异度95.9%。

要点

  • 非侵袭性子宫内膜样肿瘤中,2023版FIGO分期MRI诊断准确性显著低于2009版(kappa 0.66 vs 0.82)。
  • MRI对深肌层浸润(≥50%)诊断敏感度87.0%、特异度95.9%,性能可靠。
  • 侵袭性肿瘤中两版分期系统诊断一致性无显著差异(p=0.160)。

核心结论

  • 2023版FIGO分期修订对MRI分期准确性带来可测量的挑战,尤其在局限于子宫的非侵袭性子宫内膜肿瘤中;但MRI对深肌层浸润仍保持可靠诊断性能,支持其继续用于术前分期。

研究设计与样本

  • 回顾性研究,纳入432例(平均年龄54.9岁)经组织病理学确诊的FIGO 2009 I期子宫内膜癌患者,均行术前MRI;按肿瘤侵袭性分为非侵袭性组(n=364,低级别子宫内膜样组织学)和侵袭性组(n=68,3级子宫内膜样或非子宫内膜样组织学,包括浆液性、透明细胞癌和癌肉瘤);以组织病理学为参考标准,将肌层浸润深度分为无浸润、浅浸润(<50%)和深浸润(≥50%)。

诊断标准与关键数值

  • 非侵袭性肿瘤中,2009版FIGO分期MRI与病理分期一致性kappa 0.82(95%CI 0.74-0.89),2023版kappa 0.66(95%CI 0.59-0.74),差异有统计学意义(p=0.0029);MRI对深肌层浸润诊断敏感度87.0%、特异度95.9%;侵袭性肿瘤中两版分期系统差异无统计学意义(p=0.160);淋巴血管间隙浸润存在与否对MRI与病理分期诊断一致性无统计学显著差异(p=0.452)。

临床应用与阅片要点

  • 放射科医生应认识到2023版FIGO标准下检测无肌层浸润的诊断准确性有统计学显著降低,尤其在非侵袭性子宫内膜样肿瘤中,可考虑整合互补的定量影像参数或分子生物标志物以提高术前分期精度(作者建议)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to evaluate the diagnostic performance of Magnetic Resonance Imaging (MRI) for staging patients with International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial cancer, by comparing the original 2009 system with the revised 2023 system.

MATERIALS AND METHODS: This retrospective study included 432 patients (mean age, 54.9 years) with histopathologically confirmed FIGO 2009 stage I endometrial cancer who underwent preoperative MRI. The patients were categorized into non-aggressive (n = 364; low-grade endometrioid histology) and aggressive (n = 68; grade 3 endometrioid or non-endometrioid histology, including serous, clear cell carcinoma, and carcinosarcoma) tumor groups. Preoperative MRI-based assessment of myometrial invasion was compared with histopathological results to assess the myometrial invasion depth, which was classified as no invasion, superficial invasion (< 50%), and deep invasion (≥ 50%). Diagnostic accuracy, sensitivity, specificity, and agreement of preoperative MRI-based staging determination were calculated for both FIGO 2009 and 2023 systems.

RESULTS: In non-aggressive tumors, the 2009 FIGO staging demonstrated superior accuracy (kappa 0.82, 95% CI 0.74-0.89) compared to the 2023 staging (kappa 0.66, 95% CI 0.59-0.74), with a statistically significant difference (p = 0.0029). MRI performance varied across invasion depths, with excellent diagnostic accuracy for deep myometrial invasion (sensitivity, 87.0%; specificity, 95.9%). For aggressive tumors, no significant difference was observed between the two staging systems (p = 0.160). Subgroup analysis demonstrated that the presence of lymphovascular space invasion did not result in statistically significant differences in diagnostic agreement between MRI and pathological staging (p = 0.452).

CONCLUSION: This study provides evidence that 2023 FIGO staging revisions present measurable challenges for MRI-based staging accuracy, particularly in the assessment of non-aggressive endometrial tumors confined to the uterus. Despite these challenges, MRI maintains reliable diagnostic performance for detecting deep myometrial invasion in uterus-confined disease, supporting its continued utility in preoperative staging protocols. KEY TAKE‑HOME: Radiologists should recognize the statistically significant reduction in diagnostic accuracy for detecting the absence of myometrial invasion under FIGO 2023 criteria, particularly in non-aggressive endometrioid tumors, and consider integrating complementary quantitative imaging parameters or molecular biomarkers to enhance the preoperative staging precision.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Lee SL, Shin YR, Kim H, et al. Impact of the 2023 FIGO staging revision on MRI diagnostic accuracy in FIGO 2009 stage I endometrial cancer. Abdom Radiol (NY). 2025. PMID: 40856808. doi:10.1007/s00261-025-05174-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。